

Jose Carlos Ruffinelli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8592437/publications.pdf>

Version: 2024-02-01

10
papers

104
citations

1684129

5
h-index

1474186

9
g-index

10
all docs

10
docs citations

10
times ranked

172
citing authors

#	ARTICLE	IF	CITATIONS
1	New advances in the clinical management of RAS and BRAF mutant colorectal cancer patients. Expert Review of Gastroenterology and Hepatology, 2021, 15, 65-79.	3.0	4
2	Ectopic Cushing's syndrome due to thymic neuroendocrine tumours: a systematic review. Reviews in Endocrine and Metabolic Disorders, 2021, 22, 1041-1056.	5.7	9
3	Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics. European Journal of Cancer, 2021, 151, 211-220.	2.8	24
4	Silibinin Suppresses Tumor Cell-Intrinsic Resistance to Nintedanib and Enhances Its Clinical Activity in Lung Cancer. Cancers, 2021, 13, 4168.	3.7	8
5	Fasting plasma glucose is an independent predictor of survival in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy. BMC Cancer, 2019, 19, 165.	2.6	24
6	Incidence, predictors and prognostic significance of thromboembolic disease in patients with advanced <i>ALK</i> -rearranged non-small cell lung cancer. European Respiratory Journal, 2018, 51, 1702431.	6.7	32
7	Colorectal surgery in the elderly: Does the extreme age determine the odds ratio of complications?. Journal of Clinical Oncology, 2018, 36, e22046-e22046.	1.6	1
8	Oncogeriatric screening in patients with colorectal cancer: Is it a good tool for making decisions about their treatment?. Journal of Clinical Oncology, 2018, 36, e22049-e22049.	1.6	0
9	Geriatric assessment to predict toxicity in elderly patients with unresectable locally advanced non-small-cell lung cancer treated with concurrent chemoradiotherapy.. Journal of Clinical Oncology, 2018, 36, 8557-8557.	1.6	1
10	A prospective study assessing the value of geriatric assessment in elderly patients with stage III NSCLC for concurrent chemoradiation.. Journal of Clinical Oncology, 2016, 34, 8509-8509.	1.6	1